Equity Overview
Price & Market Data
Price: $0.483
Daily Change: -$0.0143 / 2.96%
Range: $0.454 - $0.51
Market Cap: $15,355,826
Volume: 202,273
Performance Metrics
1 Week: 4.32%
1 Month: -28.04%
3 Months: -34.88%
6 Months: -57.26%
1 Year: -71.08%
YTD: -58.00%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.